BioEclosion aims at quantitative diagnotics based on fast and user-friendly devices against clear molecular markers of emerging and expanded illnesses. It started its activity with several patents, the most important being Celifast: a non-intrusive system developed for the detection of Celiac Disease. Clearly aimed at point of care (POC) attention to patients, the core technology has been successfully validated and the team now works on the best device for its commercialization.


BioEclosion also owns a wide savoir-faire at the Biological Chemistry interface and bet for using them as a net between academia and private sectors.


Bioeclosion is the result of a large series of initiatives of tecnological transfer. In particular, CeliFast has concentrated most of the rewards in a series of national and regional challenges.

Prize Richi Social Enterpreneur

Selected participant for Richi Social Entrepreneurs Autumn 2017

Prize OneStart

Semi-finalist at One-Start 2016

1st Prize 4th Edition of Valortec 2014

2nd Prize Ideas Generation Program 2013

BioEclosion also closely works in collaboration with several entities for the promotion of technological transfer.


About us

BioEclosion is a young company resulting from the efforts of its founders and the Universitat Autònoma de Barcelona. Born in 2016, its main objective is the development and production of new diagnotic devices based on last generation Biosensors.

Ph.D. Jofre Ferrer-Dalmau

Responsibilities: Chief Executive Officer

He is the cofounder and Chief Executive Officer at Company, Spain. He is Ph.D. in Biomedicine and a degree in Biotechnology and Biochemistry from Autonomous University of Barcelona. At 2014, he joined Envigo for two years where he became a pre-clinical stutdy director highly experienced in GLP compliance. Since 2016, he has been working in BioEclosion and as Assistant Professor in Autonomous University of Barcelona. He is currently finishing a MBA at Escuela de Administración de Empresas (EAE).

More Info

Prof. María Isabel Pividori

Responsibilities: Chief Technological Officer (CTO) and Scientific Advisor

She is the cofounder and Chief Technological Officer at Company, Spain. She iscurrently an Associate Professor at the UAB (Researcher ID K-9602- 2015, 5266-7873). She holds the B.A. degree in biochemistry. She received her Ph.D. in chemistry in 2002. Prof. Pividori belongs to the Group of Sensors and Biosensors (GSB), recognized by AGAUR as a consolidated research group since 2005 (2014 SGR 0837). This group has been working continuously since 1980 on the design of hand-held, user-friendly, low cost analytical instrumentation, with more than 450 papers in this topic, and funded by the National Programme of Biotechnology (BIO93-0635, BIO-0981- E, BIO96-0740, BIO2000-0681, BIO2004-02776, BIO2007- 63300, BIO2010-17566, BIO2013-41242, BIO2016-75751- R) beside other European and international programs. Relevant data about the IP are the h-index (26) and the number of scientific publication (112) being 78 scientific articles in indexed journals (70 % Q1) and 2 patents. The IP has supervised 6 doctoral dissertations, and 3 ongoing doctoral thesis. The number of citation is 1794, with a citation/article ratio of 20.62 and an average citation per year of 169. Isabel Pividori was principal investigator of 10 research projects and invited speaker in 25 conferences.

More Info

Ph.D. Ona Illa

Responsibilities: Executive Scientific

She is the cofounder and Executive Scientific at Company, Spain. She studied Chemistry at the Universitat Autònoma de Barcelona (UAB), Spain. She then undertook her PhD studies with in the same university. In 2006, she was a visiting postdoctoral fellow with Prof. A. Baceiredo in Toulouse, France. In June 2006, she joined the group of Prof. V. Aggarwal at the University of Bristol, UK. Since 2008 she has been an Assistant Professor in the Organic Chemistry Section at the UAB and her current research interests include the design, synthesis and structural study of new molecules (mainly peptides) for applications in Biomedicine and Materials Science. She is organic chemist experienced in the synthesis and use of non-natural peptides and who has been working on projects funded by the National Programme of Chemical Science and Technologies (BQU2001-1907, CTQ2004-01067, CTQ2010-15408,CTQ2013-43754).

More Info

Ph.D. Jean-Didier Maréchal

Responsibilities: Executive Scientific

He is the cofounder and Executive Scientific at Company, Spain. He is currently an Associate Professor at the Universitat Autònoma de Barcelona (UAB). He was trained at the Ecole Normale Supérieure in Paris. Doctor in Chemical Sciences from the UAB and the University Paris Sud. Specialist in structural bioinformatics. He worked for several years in the field of drug design in UK and France both universities and multinational companies and spin-offs. UAB reinstated in 2006, leads a group of molecular design oriented biotechnological systems whose team is mainly dedicated to the development of integrative computational approaches for biomedicinal and biotechnological applications. Our research interests are broad although principally articulated around two main blocks: the study and prediction of drug efficiency and toxicological profiles (ADME and side effects) and the development of artificial enzymes.

More Info